| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | President &CEO | Head of Research &Development +4 more
2 companies
Sandrock Alfred is a President and CEO at VYGR, with reported holdings spanning 2 companies. Recent filings cover 0 purchases and 34 sales. Those positions are worth an estimated $6.3M at current prices.
Our model assigns Sandrock Alfred a middling insider score of 69/100, based on 9 past trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of +21.7%.
Sandrock Alfred's largest disclosed position is in BIIB as Head of Research &Development, worth about $4.5M. The recent filings there lean toward selling, a net 23,549 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2021 | BIIB Biogen Inc. | Head of Research &Development | Sell | 7,672 | $440.00 | $3,375,680.00 | -43.0% | -17.3% | -49.2% | |
| Nov 4, 2020 | BIIB Biogen Inc. | EVP, Research &Development | Sell | 1,500 | $350.00 | $525,000.00 | -10.3% | - | - | |
| Feb 27, 2018 | BIIB Biogen Inc. | EVP, Chief Medical Officer | Sell | 259 | $290.83 | $75,324.97 | -3.8% | - | - | |
| Feb 23, 2018 | BIIB Biogen Inc. | EVP, Chief Medical Officer | Sale+OE | 908 | $293.44 | $266,443.52 | -12.2% | - | - | |
| Feb 20, 2018 | BIIB Biogen Inc. | EVP, Chief Medical Officer | Sell | 743 | $292.00 | $216,956.00 | -10.2% | - | - | |
| Feb 15, 2018 | BIIB Biogen Inc. | EVP, Chief Medical Officer | Sell | 1,294 | $298.85 | $386,711.90 | -15.1% | - | - | |
| Apr 3, 2017 | BIIB Biogen Inc. | EVP CMO Neuro &Neurodegenerat | Sell | 1,981 | $274.08 | $542,952.48 | -21.9% | - | - | |
| Mar 1, 2017 | BIIB Biogen Inc. | EVP CMO Neuro &Neurodegenerat | Sell | 973 | $290.07 | $282,238.11 | -9.7% | - | - | |
| Feb 25, 2016 | BIIB Biogen Inc. | EVP CMO Neuro &Neurodegenerat | Sell | 183 | $261.90 | $47,927.70 | -2.2% | - | - | |
| Feb 17, 2016 | BIIB Biogen Inc. | EVP CMO Neuro &Neurodegenerat | Sell | 722 | $256.16 | $184,947.52 | -8.3% | - | - |